PDCD1 and melanoma: While baseline density does not appear to correlate with clinical activity of ipilimumab, pre-existing CD8+ (but not CD4+) T cell infiltration at the invasive tumor margin and within the tumor core is associated with response to anti-PD-1 therapy in patients with melanoma.